Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-05
DOI
10.1007/s10637-020-00910-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
- (2019) Davide Melisi et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
- (2018) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
- (2017) David Capper et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor
- (2017) Florian Gessler et al. World Neurosurgery
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- Temozolomide induced bone marrow Suppression-A single institution outcome analysis and review of the literature
- (2015) Taxiarchis V. Kourelis et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
- (2015) Armin Maier et al. CELLULAR ONCOLOGY
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- (2015) Michael Lahn et al. Drug Design Development and Therapy
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
- (2014) Richard J. Kovacs et al. Cardiovascular Toxicology
- First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
- (2014) Jordi Rodon et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
- (2014) Jordi Rodón et al. INVESTIGATIONAL NEW DRUGS
- Sustained CD4+T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide
- (2014) Susannah Ellsworth et al. OncoImmunology
- Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
- (2012) M J McCoy et al. BRITISH JOURNAL OF CANCER
- Blockade of TGF- Signaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma
- (2011) M. Zhang et al. CANCER RESEARCH
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
- (2011) C. E. Fadul et al. NEURO-ONCOLOGY
- Roles for the type III TGF-β receptor in human cancer
- (2010) Catherine E. Gatza et al. CELLULAR SIGNALLING
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now